A panel of experts has forwarded the reports based on clinical trials recommending Bharat Biotech’s corona vaccine – Covaxin for children of 2-12 years old.
“Bharat Biotech has submitted data from clinical trials in the two – 18 age group for Covaxin to CDSCO (Central Drugs Standard Control Organisation). The data has been thoroughly reviewed by the Subject Expert Committee (SEC)… provided positive recommendations,” the company based in Hyderabad said.
“This represents one of the first approvals worldwide for COVID-19 vaccines for the two – 18 age group… We now await further regulatory approvals prior to product launch and market availability of Covaxin for Children,” said the company.
“We (always) said we will get a vaccine for children between two and 18… it will be approved soon. SEC has recommended… it will be approved soon… trials were conducted keeping in mind safety of children. We are committed to their safety,” Dr Bharti Pravin Pawar, junior Health Minister spoke to NDTV.
Though final approval is viewed just a formality – is yet to be given by Drug Controller General of India.
Earlier this month India’s vaccine task force chief Dr NK Arora, informed ANI that children with extreme comorbidities would get priority and rest healthier children will be immunised subsequently.
“We are trying to identify (children) at highest risk… within the next couple of weeks, the list will be in the public domain. We are also making arrangements so these children do not have to travel (too far) to get the vaccine…” he said.